Clinical and pathological analysis of IgA nephropathy with chronic renal failure

Figures & data

Table 1. Clinical characteristics of 65 cases.

		eGRF (mL/min)
Indexes	X ± S	31–60 (Group A)	≤30 (Group B)	p
Age (years)	37.2 ± 12.8	38.8 ± 12.6	34.2 ± 13.0	0.169
Disease curse (month)	19.0 ± 42.1	19.2 ± 42.7	18.6 ± 41.8	0.962
Systolic pressure (mmHg)	142 ± 19	139 ± 19	149 ± 19	0.048
Diastolic pressure (mmHg)	90 ± 13	87 ± 10	94 ± 16	0.094
MAP (mmHg)	107 ± 14	105 ± 12	112 ± 17	0.032
Alb (g/L)	32.1 ± 8.6	34.5 ± 7.9	27.9 ± 8.2	0.003
BUN (mmol/L)	9.42 ± 3.40	7.98 ± 2.49	12.60 ± 3.00	0.000
Scr (umol/L)	198.0 ± 81.9	153.9 ± 21.5	278.4 ± 90.4	0.000
UA (umol/L)	453.4 ± 105.6	429.4 ± 95.6	496.2 ± 111.0	0.014
TG (mmol/L)	2.16 ± 1.39	2.13 ± 1.55	2.21 ± 1.12	0.826
CHOL (mmol/L)	5.79 ± 2.18	5.41 ± 1.56	6.41 ± 2.86	0.083
URBC (×103/mL)	133.7 ± 179.4	145.2 ± 210.5	112.7 ± 101.5	0.405
Urinary protein (g/24h)	2.98 ± 2.77	2.05 ± 2.13	4.67 ± 3.03	0.000
Serum IgG (g/L)	9.08 ± 4.28	10.32 ± 3.68	6.84 ± 4.47	0.004
Serum IgA (g/L)	2.83 ± 1.34	2.87 ± 1.26	2.75 ± 1.49	0.773
Serum IgM (g/L)	1.37 ± 0.75	1.33 ± 0.75	1.42 ± 0.76	0.680
Serum C3 (g/L)	0.991 ± 0.247	0.980 ± 0.232	1.010 ± 0.277	0.684
Serum C4 (g/L)	0.289 ± 0.184	0.257 ± 0.087	0.342 ± 0.273	0.116

Table 2. Relationship between the levels of clinical indicators and eGRF level.

Indexes	Correlation coefficient	p
Systolic pressure	−0.331	0.007
MAP	−0.260	0.037
Urinary protein	−0.469	0.000
Alb	0.461	0.001
BUN	−0.624	0.000
Scr	−0.863	0.000
UA	−0.304	0.015
Serum IgG	0.463	0.000

Figure 1. Pathological diagnoses distribution of 65 cases by WHO Classifications.

Figure 2. Pathological diagnoses distribution of 65 cases by Oxford Classifications.

Table 3. Different pathological lesions of 65 cases.

Index	Number (N)	Percentage (%)
Global and segmental sclerosis
0/<25%/25%–50%/50%–75%/≥75%	1/8/10/23/23	1.5/12.3/15.4/35.4/35.4
Global sclerosis
0/<25%/25%–50%/50%–75%/≥75%	3/12/23/21/6	4.6/18.5/35.4/32.3/9.2
Segmental sclerosis
0/<25%/25%–50%/50%–75%/≥75%	11/35/18/1/0	16.9/53.8/27.7/1.5/0.0
Mesangial cell proliferation
(I/II/III)	47/17/1	72.3/26.2/1.5
Interstitial fibrosis/Tubular atrophy)
0/<25%/25%–50%/≥50%	16/25/18/6	24.6/38.5/27.7/9.2
Crescent formation
Absent/Present	50/15	76.9/23.1
Capsular adhesion
Absent/Present	57/8	87.7/12.3
Pericapsular fibrosis
Absent/Present	54/11	83.1/16.9

I: mild lesion; II: moderate lesion; III: serious lesion.

Table 4. Immunofluorescence tests results of 65 cases.

		eGRF (mL/min)
Immune deposits	N, %	31–60 (Group A)	≤30 (Group B)	p
IgG	10 (15.4)	8 (19.9)	2 (8.7)	0.455
IgM	28 (43.1)	19 (42.9)	9 (39.1)	0.961
C3	29 (44.6)	17 (40.5)	12 (52.2)	0.364
C1q	3 (4.6)	0 (0.0)	3 (13.0)	0.041
Fbri	1 (1.5)	1 (2.4)	0 (0.0)	1.000

Figure 3. Relationship between Scr level and the Katafuchi semiquantitative score.

Figure 4. Relationship between eGFR level and the Katafuchi semiquantitative score.